Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CHRS's Cash to Debt is ranked higher than
63% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. CHRS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CHRS' s 10-Year Cash to Debt Range
Min: 9.41  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.25
CHRS's Equity to Asset is ranked lower than
87% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CHRS: 0.25 )
Ranked among companies with meaningful Equity to Asset only.
CHRS' s 10-Year Equity to Asset Range
Min: -2.05  Med: 0.14 Max: 0.36
Current: 0.25
-2.05
0.36
Z-Score: 3.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -263.11
CHRS's Operating margin (%) is ranked lower than
65% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. CHRS: -263.11 )
Ranked among companies with meaningful Operating margin (%) only.
CHRS' s 10-Year Operating margin (%) Range
Min: -2028.33  Med: -1308.36 Max: -207.94
Current: -263.11
-2028.33
-207.94
Net-margin (%) -308.19
CHRS's Net-margin (%) is ranked lower than
68% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. CHRS: -308.19 )
Ranked among companies with meaningful Net-margin (%) only.
CHRS' s 10-Year Net-margin (%) Range
Min: -1949.65  Med: -1738.70 Max: -280.12
Current: -308.19
-1949.65
-280.12
ROA (%) -86.77
CHRS's ROA (%) is ranked lower than
82% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. CHRS: -86.77 )
Ranked among companies with meaningful ROA (%) only.
CHRS' s 10-Year ROA (%) Range
Min: -145  Med: -109.63 Max: -74.26
Current: -86.77
-145
-74.26
ROC (Joel Greenblatt) (%) -3120.57
CHRS's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. CHRS: -3120.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CHRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5546.99  Med: -4113.43 Max: -2679.87
Current: -3120.57
-5546.99
-2679.87
» CHRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CHRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 31.04
CHRS's P/B is ranked lower than
95% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. CHRS: 31.04 )
Ranked among companies with meaningful P/B only.
CHRS' s 10-Year P/B Range
Min: 6.35  Med: 21.74 Max: 32.32
Current: 31.04
6.35
32.32
P/S 6.29
CHRS's P/S is ranked higher than
67% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. CHRS: 6.29 )
Ranked among companies with meaningful P/S only.
CHRS' s 10-Year P/S Range
Min: 1.98  Med: 4.48 Max: 6.54
Current: 6.29
1.98
6.54
EV-to-EBIT -11.75
CHRS's EV-to-EBIT is ranked lower than
473% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. CHRS: -11.75 )
Ranked among companies with meaningful EV-to-EBIT only.
CHRS' s 10-Year EV-to-EBIT Range
Min: -12.6  Med: -8.00 Max: -1.6
Current: -11.75
-12.6
-1.6
Current Ratio 2.77
CHRS's Current Ratio is ranked lower than
65% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. CHRS: 2.77 )
Ranked among companies with meaningful Current Ratio only.
CHRS' s 10-Year Current Ratio Range
Min: 0.85  Med: 2.67 Max: 3.46
Current: 2.77
0.85
3.46
Quick Ratio 2.77
CHRS's Quick Ratio is ranked lower than
62% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. CHRS: 2.77 )
Ranked among companies with meaningful Quick Ratio only.
CHRS' s 10-Year Quick Ratio Range
Min: 0.85  Med: 2.67 Max: 3.46
Current: 2.77
0.85
3.46
Days Sales Outstanding 22.07
CHRS's Days Sales Outstanding is ranked higher than
82% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. CHRS: 22.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
CHRS' s 10-Year Days Sales Outstanding Range
Min: 28.36  Med: 30.37 Max: 36.88
Current: 22.07
28.36
36.88

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 40.79
CHRS's Price/Net Current Asset Value is ranked lower than
91% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. CHRS: 40.79 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CHRS' s 10-Year Price/Net Current Asset Value Range
Min: 9.22  Med: 22.39 Max: 35.56
Current: 40.79
9.22
35.56
Price/Tangible Book 34.06
CHRS's Price/Tangible Book is ranked lower than
94% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. CHRS: 34.06 )
Ranked among companies with meaningful Price/Tangible Book only.
CHRS' s 10-Year Price/Tangible Book Range
Min: 8.59  Med: 19.14 Max: 29.69
Current: 34.06
8.59
29.69
Price/Median PS Value 1.41
CHRS's Price/Median PS Value is ranked lower than
60% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. CHRS: 1.41 )
Ranked among companies with meaningful Price/Median PS Value only.
CHRS' s 10-Year Price/Median PS Value Range
Min: 0.57  Med: 0.90 Max: 1.23
Current: 1.41
0.57
1.23
Earnings Yield (Greenblatt) (%) -8.50
CHRS's Earnings Yield (Greenblatt) (%) is ranked lower than
60% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CHRS: -8.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CHRS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -13  Med: 0.00 Max: 0
Current: -8.5
-13
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
» More Articles for CHRS

Headlines

Articles On GuruFocus.com
A Look at Pharma Company Dermira's Performance Mar 27 2015 

More From Other Websites
Coherus BioSciences to Report Second Quarter 2015 Financial Results on August 10 Jul 28 2015
Coherus BioSciences to Report Second Quarter 2015 Financial Results on August 10 Jul 28 2015
Coherus Biosciences (CHRS) in Focus: Stock Surges 10.7% - Tale of the Tape Jul 13 2015
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 08 2015
Ascena Retail Group, Inc. -- Moody's assigns Ba2 Corporate Family Rating to Ascena Retail Group;... Jun 24 2015
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 12 2015
Coherus Biosciences (CHRS) is Overbought: Is A Drop Coming? - Tale of the Tape Jun 11 2015
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 27 2015
Coherus BioSciences to Present at Jefferies Healthcare Conference on June 3 May 27 2015
Coherus BioSciences to Present at Jefferies Healthcare Conference on June 3 May 27 2015
COHERUS BIOSCIENCES, INC. Financials May 19 2015
Coherus BioSciences Reports First Quarter 2015 Financial and Operating Results May 11 2015
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other... May 11 2015
Coherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today May 11 2015
Coherus BioSciences Reports First Quarter 2015 Financial and Operating Results May 11 2015
Coherus BioSciences to Report First Quarter 2015 Financial Results on May 11 May 04 2015
Coherus BioSciences to Report First Quarter 2015 Financial Results on May 11 May 04 2015
Coherus BioSciences to Present at Deutsche Bank Health Care Conference on May 7 Apr 30 2015
Baxter (BAX) Beats Q1 Earnings Estimates, Sales Down Y/Y - Analyst Blog Apr 24 2015
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events Apr 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK